### Edgar Filing: Anthera Pharmaceuticals Inc - Form 4

Anthera Pha Form 4 January 29,	armaceuticals Inc 2013	;										
FORN Check th if no lon subject t Section	<b>A</b> 4 UNITED	Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF							OMB APPROVAL OMB Number: 3235-0287 January 31, 2005 Estimated average burden hours per			
Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940									0.5			
(Print or Type Responses)												
1. Name and Address of Reporting Person <u>*</u> ORBIMED ADVISORS LLC				ier Name <b>a</b> i	nd Ticker or T	rading		5. Relationship of Reporting Person(s) to Issuer				
	Anthera Pharmaceuticals Inc [ANTH]					(Check all applicable)						
				(Month/Dav/Year) —				X Director 10% Owner Officer (give title Other (specify low) below)				
(Street) 4. If A Filed(N			led(Month/Day/Year) Ap				. Individual or Joint/Group Filing(Check pplicable Line) Form filed by One Reporting Person X_ Form filed by More than One Reporting					
	RK, NY 10022							rson		porting		
(City)	(State)	(Zip)		ble I - Non			-	ed, Disposed of, o	or Beneficiall	y Owned		
	2. Transaction Date (Month/Day/Year)	2A. Deeme Execution any (Month/Da	Date, if	3. Transactic Code (Instr. 8) Code V	4. Securities A orDisposed of ( (Instr. 3, 4 an Amount	D)	red (A) or Price	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common Stock	01/25/2013			P	1,762,000	A	\$ 0.6484 (4)	1,762,000	Ι	See Footnotes (1) $(2)$ $(3)$		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Secur	ınt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

### Edgar Filing: Anthera Pharmaceuticals Inc - Form 4

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>		Relationships						
hoporting o who	Director	10% Owner	Officer	Other				
ORBIMED ADVISOR 601 LEXINGTON AV NEW YORK, NY 100	ENUE, 54TH FLOOR	Х						
OrbiMed Capital GP IV 601 LEXINGTON AV NEW YORK, NY 100	Х							
ISALY SAMUEL D 601 LEXINGTON AV NEW YORK, NY 1002	Х							
Signatures								
/s/ Samuel D. Isaly	01/29/2013							

Isaly \*\*Signature of Reporting Person

# **Explanation of Responses:**

If the form is filed by more than one reporting person, see Instruction 4(b)(v).

Date

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The shares of Common Stock ("Shares") reported herein as indirectly beneficially owned by OrbiMed Capital GP IV LLC ("OrbiMed Capital"), OrbiMed Advisors LLC ("OrbiMed Advisors") and Samuel D. Isaly ("Isaly") are directly owned by OrbiMed Private

(1) Investments IV, LP ("OPI IV"), and each of OrbiMed Capital, OrbiMed Advisors and Isaly may be deemed to have a pecuniary interest in Shares beneficially owned by OPI IV. This Form 4 is being jointly filed by OrbiMed Capital, OrbiMed Advisors and Isaly.

OrbiMed Capital is the sole general partner of OPI IV. OrbiMed Advisors is a registered adviser under the Investment Advisers Act of 1940, as amended, and the sole managing member of OrbiMed Capital. OrbiMed Advisors and OrbiMed Capital may be deemed to have

- (2) beneficial ownership of the Shares reported herein by virtue of such relationships and the authority of OrbiMed Capital to direct the vote and disposition of the Shares held by OPI IV. Isaly, a natural person, may be deemed to have beneficial ownership of the Shares reported herein in his capacity as the holder of a controlling interest in OrbiMed Advisors.
- (3) Each of OrbiMed Advisors, OrbiMed Capital and Isaly disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary

### Edgar Filing: Anthera Pharmaceuticals Inc - Form 4

interest therein, if any. This report shall not be deemed an admission that the reporting persons are beneficial owners for the purpose of Section 16 of the Exchange Act, or for any other purpose.

The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from \$0.6430 to \$0.6500, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer or the Staff of

(4) \$0.0450 to \$0.0500, inclusive. The reporting persons undertake to provide to the issuer, any security notice of the issuer of the start of the Securities and Exchange Commission, upon request, full information regarding the number of Shares sold at each separate price within the range set forth in this footnote.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.